Summary:
- The U.S. Food and Drug Administration (FDA) has developed an AI-powered tool to help review and approve new medical products more efficiently.
- However, the rollout of this tool has faced challenges, with concerns raised about its accuracy and potential biases in the data it uses.
- Experts suggest that the FDA should take a more cautious and transparent approach to implementing AI technologies, to ensure they are reliable and do not perpetuate existing biases in the healthcare system.